Daniel N. Swisher, Jr. Sells 2,200 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $72.06, for a total value of $158,532.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Thursday, April 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $70.22, for a total value of $154,484.00.

Corcept Therapeutics Stock Performance

Shares of Corcept Therapeutics stock opened at $73.36 on Friday. The stock has a market cap of $7.78 billion, a PE ratio of 58.22 and a beta of 0.22. The business has a fifty day simple moving average of $68.17 and a 200-day simple moving average of $61.44. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12 month low of $27.30 and a 12 month high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, hitting the consensus estimate of $0.17. The business had revenue of $157.21 million during the quarter, compared to analysts’ expectations of $177.93 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. Corcept Therapeutics’s revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.25 earnings per share. On average, sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CORT. HC Wainwright cut their price objective on Corcept Therapeutics from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Piper Sandler increased their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a research report on Thursday, April 3rd. Truist Financial set a $135.00 price objective on Corcept Therapeutics in a research report on Tuesday, May 6th. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Finally, StockNews.com cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $138.25.

Institutional Trading of Corcept Therapeutics

Institutional investors have recently bought and sold shares of the company. Brooklyn Investment Group boosted its position in Corcept Therapeutics by 99.5% during the first quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 186 shares during the last quarter. Kestra Investment Management LLC acquired a new stake in Corcept Therapeutics during the fourth quarter valued at $27,000. MassMutual Private Wealth & Trust FSB boosted its position in Corcept Therapeutics by 102.0% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 620 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 313 shares during the last quarter. Covestor Ltd boosted its position in Corcept Therapeutics by 1,741.2% during the first quarter. Covestor Ltd now owns 626 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 592 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in Corcept Therapeutics by 1,150.8% during the first quarter. IFP Advisors Inc now owns 738 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 679 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.